What question did this study set out to answer?

This research aims to identify alterations in plasma apolipoprotein levels in pancreatic cancer patients compared to healthy controls.

October 8, 2012PLoS ONEOpen Access

Altered Plasma Apolipoprotein Modifications in Patients with Pancreatic Cancer: Protein Characterization and Multi-Institutional Validation

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies specific apolipoprotein changes in pancreatic cancer patients, suggesting potential biomarkers for detection.

This research aims to identify alterations in plasma apolipoprotein levels in pancreatic cancer patients compared to healthy controls.
Compared plasma protein profiles of 112 pancreatic cancer patients with 103 healthy controls using a new mass spectrometry system.
Validated findings in a total of 1099 plasma/serum samples from multiple cohorts across 8 medical institutions.
Significantly decreased levels of hemi-truncated apolipoprotein AII dimer and unglycosylated apolipoprotein CIII in pancreatic cancer patients (P<0.0001).
Area-under-curve values for biomarkers showed strong predictive capability, with values of 0.877, 0.798, and 0.903.

Honda et al. (2012) studied this question.

View Full Paper

Ask AI

Bookmark